Response to letter entitled: Re: 'Inadequacy of PCR genotyping in advanced non-small cell lung cancer: EGFR L747_A755delinsSS exon 19 deletion is not detected by the real-time PCR Idylla EGFR mutation test but is detected by ctDNA NGS and responds to osimertinib': Not looking back.
作者信息
O'Sullivan Hazel, d'Arienzo Paolo D, Yousaf Nadia, Cui Wanyuan, Popat Sanjay
机构信息
Lung Unit, Royal Marsden NHS Foundation Trust, London, United Kingdom.
Lung Unit, Royal Marsden NHS Foundation Trust, London, United Kingdom; Thoracic Oncology, Institute of Cancer Research, London, United Kingdom.
出版信息
Eur J Cancer. 2022 Oct;174:318-320. doi: 10.1016/j.ejca.2022.06.040. Epub 2022 Aug 7.
PMID:35948502
Abstract
摘要
相似文献
1
Response to letter entitled: Re: 'Inadequacy of PCR genotyping in advanced non-small cell lung cancer: EGFR L747_A755delinsSS exon 19 deletion is not detected by the real-time PCR Idylla EGFR mutation test but is detected by ctDNA NGS and responds to osimertinib': Not looking back.对题为《回复：“晚期非小细胞肺癌中PCR基因分型的不足：实时PCR Idylla EGFR突变检测未检测到EGFR L747_A755delinsSS外显子19缺失，但ctDNA NGS检测到并对奥希替尼有反应”》的信的回复：不回头。
Eur J Cancer. 2022 Oct;174:318-320. doi: 10.1016/j.ejca.2022.06.040. Epub 2022 Aug 7.
2
Re: Inadequacy of PCR genotyping in advanced non-small cell lung cancer: EGFR L747_A755delinsSS Exon 19 deletion is not detected by the real-time PCR IdyllaTM EGFR mutation test but is detected by ctDNA NGS and responds to osimertinib.关于：晚期非小细胞肺癌中PCR基因分型的不足：实时PCR IdyllaTM表皮生长因子受体（EGFR）突变检测未检测到外显子19的EGFR L747_A755delinsSS缺失，但循环肿瘤DNA（ctDNA）下一代测序（NGS）检测到该缺失，且该缺失对奥希替尼有反应。
Eur J Cancer. 2022 Oct;174:315-317. doi: 10.1016/j.ejca.2022.06.039. Epub 2022 Aug 4.
3
Inadequacy of PCR genotyping in advanced non-small cell lung cancer: EGFR L747_A755delinsSS exon 19 deletion is not detected by the real-time PCR Idylla™ EGFR mutation test but is detected by ctDNA next generation sequencing and responds to osimertinib.晚期非小细胞肺癌中PCR基因分型的不足：实时PCR Idylla™ EGFR突变检测未检测到EGFR L747_A755delinsSS外显子19缺失，但通过ctDNA下一代测序检测到该缺失，且该缺失对奥希替尼有反应。
Eur J Cancer. 2022 May;166:38-40. doi: 10.1016/j.ejca.2022.02.007. Epub 2022 Mar 8.
4
The role of comprehensive analysis with circulating tumor DNA in advanced non-small cell lung cancer patients considered for osimertinib treatment.在考虑使用奥希替尼治疗的晚期非小细胞肺癌患者中，采用循环肿瘤 DNA 进行综合分析的作用。
Cancer Med. 2021 Jun;10(12):3873-3885. doi: 10.1002/cam4.3929. Epub 2021 May 12.
5
Clearing of circulating tumour DNA predicts clinical response to osimertinib in EGFR mutated lung cancer patients.循环肿瘤 DNA 清除预测 EGFR 突变型肺癌患者对奥希替尼的临床反应。
Lung Cancer. 2020 May;143:67-72. doi: 10.1016/j.lungcan.2020.03.020. Epub 2020 Mar 19.
6
Circulating tumor DNA analysis of EGFR-mutant non-small cell lung cancer patients receiving osimertinib following previous tyrosine kinase inhibitor treatment.先前接受过酪氨酸激酶抑制剂治疗的表皮生长因子受体（EGFR）突变型非小细胞肺癌患者接受奥希替尼治疗后的循环肿瘤DNA分析
Lung Cancer. 2020 Jul;145:173-180. doi: 10.1016/j.lungcan.2020.04.039. Epub 2020 May 11.
7
Predicting osimertinib-treatment outcomes through EGFR mutant-fraction monitoring in the circulating tumor DNA of EGFR T790M-positive patients with non-small cell lung cancer (WJOG8815L).通过检测 EGFR T790M 阳性非小细胞肺癌患者循环肿瘤 DNA 中的 EGFR 突变等位基因丰度预测奥希替尼治疗效果（WJOG8815L）。
Mol Oncol. 2021 Jan;15(1):126-137. doi: 10.1002/1878-0261.12841. Epub 2020 Nov 17.
8
A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2.一项评估奥希替尼用于经液体活检检测到 EGFR T790M 突变的非小细胞肺癌二线治疗的 II 期临床试验：LiquidLung-O-队列 2。
Cancer Res Treat. 2019 Apr;51(2):777-787. doi: 10.4143/crt.2018.387. Epub 2018 Sep 7.
9
Osimertinib in Patients With Non-Small Cell Lung Cancer and Uncommon EGFR Mutations-Chasing Unicorns?奥希替尼用于非小细胞肺癌及罕见表皮生长因子受体（EGFR）突变患者——追逐独角兽？
JAMA Oncol. 2024 Jan 1;10(1):52-53. doi: 10.1001/jamaoncol.2023.5004.
10
Reduced sensitivity for T790M mutations using the Idylla EGFR Mutation Test.使用 Idylla EGFR Mutation Test 检测 T790M 突变时灵敏度降低。
J Clin Pathol. 2021 Jan;74(1):43-47. doi: 10.1136/jclinpath-2020-206527. Epub 2020 May 28.
引用本文的文献
1
Clinical application of liquid biopsy based on circulating tumor DNA in non-small cell lung cancer.基于循环肿瘤DNA的液体活检在非小细胞肺癌中的临床应用
Front Physiol. 2023 Jun 7;14:1200124. doi: 10.3389/fphys.2023.1200124. eCollection 2023.
Zotero 插件